NUVL
Nuvalent·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NUVL
Nuvalent, Inc.
A biotech company developing novel small molecule kinase inhibitors for cancer treatment
Biological Technology
01/25/2017
07/29/2021
NASDAQ Stock Exchange
142
12-31
Common stock
One Broadway, 14th Floor, Cambridge, MA 02142
--
Nuvalent, Inc., was incorporated under the laws of the State of Delaware on January 25, 2017. The company is a clinical-stage biopharmaceutical company focused on creating precision targeted therapies for cancer patients. The company leverages the team's deep expertise in chemistry and structure-based drug design to develop innovative small molecules designed to overcome the limitations of existing therapies on clinically proven kinase targets. Limitations faced by currently available kinase inhibitors may include (i) kinase resistance, or the emergence of new mutations in the kinase target that enable resistance to existing therapies, (ii) kinase selectivity, or existing therapies that may inhibit structurally similar kinase targets and cause off-target adverse events, and (iii) limited brain penetration, or the ability of the therapy to treat diseases that have spread or metastasized to the brain.
Company Financials
EPS
NUVL has released its 2025 Q3 earnings. EPS was reported at -1.7, versus the expected -1.32, missing expectations. The chart below visualizes how NUVL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
